In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque …

M Galluzzo, S D'Adamio, D Silvaggio… - Expert Opinion on …, 2020 - Taylor & Francis
Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …
被引用次数：47 相关文章

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque …

M Galluzzo, S D'Adamio, D Silvaggio… - Expert opinion on …, 2020 - pubmed.ncbi.nlm.nih.gov
Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque …

M Galluzzo, S D'Adamio, D Silvaggio… - EXPERT OPINION …, 2020 - art.torvergata.it
Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque …

M Galluzzo, S D'Adamio, D Silvaggio… - Expert Opinion on …, 2019 - europepmc.org
Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …